清咳平喘颗粒治疗轻中型新型冠状病毒感染的临床研究

Clinical study on Qingke Pingchuan Granules in treatment of patients with mild and moderate COVID-19 infection

目的 观察清咳平喘颗粒治疗轻型、中型新冠病毒感染患者的临床有效性及安全性。方法 选取2023年4月—2023年6月在常州市第三人民医院就诊的轻型、中型新冠病毒感染(痰热壅肺型)患者93例,按照随机数字表法将患者分为对照组(45例)和治疗组(48例)。对照组患者进行基础治疗及抗病毒治疗。治疗组在对照组治疗基础上服用清咳平喘颗粒,1袋/次,3次/d,两组疗程均为7d。观察两组患者临床疗效,比较治疗前后两组患者中医证候评分,简易咳嗽程度评分表(CET),主要临床症状消失率及C反应尿蛋白(CRP)、降钙素原(PCT)、白细胞介素-6(IL-6)等炎症指标。结果 治疗后,治疗组总有效率(97.92%)显著高于对照组(86.67%)(P<0.05)。治疗后,两组中医证候评分、咳嗽程度评分显著降低(P<0.05),且治疗组在第7天的治疗作用显著强于对照组(P<0.05)。治疗后,相比对照组,治疗组能够显著促进咳嗽症状消失(P<0.05)。治疗后,两组患者炎症指标IL-6、CRP水平显著降低(P<0.05),且治疗组显著低于对照组(P<0.05)。结论 清咳平喘颗粒联合西医常规治疗能够显著提高新冠病毒感染治疗的临床有效率,降低中医证候评分,改善患者咳嗽程度,促进咳嗽症状的缓解与消失,降低炎症水平,安全性良好,具有临床推广价值。

Objective To observe the clinical efficacy and safety of Qingke Pingchuan Granules in treatment of patients with mild and moderate COVID-19 infection.Methods Patients(93 cases)with mild and moderate COVID-19 infection in Changzhou Third People's Hospital from April 2023 to June 2023 were randomly divided into control(45 cases)and treatment(48 cases)group.Patients in the control group was treated with western medicine,and the basic treatment and antiviral treatment were carried out according to COVID-19's diagnosis and treatment plan(trial version 10).Patients in the treatment group were po administered with Qingke Pingchuan Granules on the basis of the control group,1 bag/time,three times daily.Patients in two groups were treated for 7 d.After treatment,the clinical evaluations were evaluated,the TCM syndrome scores,cough severity scores,the disappearance rate of major clinical symptoms,and inflammatory indicators in two groups before and after treatment were compared.Results After treatment,the clinical effective rate of the treatment group(97.92%)was significantly higher than that of the control group(86.67%,P<0.05).After treatment,the scores of TCM syndrome and cough degree in two groups were significantly decreased(P<0.05),and the therapeutic effect of the treatment group on the 7th day was significantly stronger than that of the control group(P<0.05).After treatment,compared with the control group,the treatment group could significantly promote the disappearance of cough symptoms(P<0.05).After treatment,the levels of inflammatory indexes IL-6 and CRP in two groups were significantly decreased(P<0.05),and which in the treatment group were significantly lower than those in the control group(P<0.05).Conclusion Qingke Pingchuan Granules in treatment of patients with mild and moderate COVID-19 infection can significantly improve the clinical effective rate,reduce the TCM syndrome score,improve the degree of cough,promote the relief and disappearance of cough symptoms,and reduce the level of inflammation,which has good safety and clinical popularization value.